The Financial Times reported on April 1, 2025, that medical device maker Becton Dickinson has initiated discussions to sell its life sciences division. The unit is reportedly valued at $21 billion.
According to the report, BD is in talks with potential competitors, including Thermo Fisher Scientific and Danaher, regarding the divestiture. This move follows earlier reports of activist investor pressure to streamline BD's portfolio.
A divestiture of this scale could significantly reshape BD's business, allowing it to focus on its core medical technology segments. Such a transaction has the potential to unlock substantial value for shareholders and optimize capital allocation for the remaining businesses.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.